Our Mission

Nanodecal's cutting-edge technology is revolutionizing the way we diagnose respiratory diseases to make possible a new paradigm in precision therapy. Our innovative solutions offer new methods for obtaining, treating, and analyzing respiratory samples with user-friendly devices that can be easily integrated into any healthcare setting. This breakthrough technology has the potential to significantly improve patient outcomes and streamline the diagnostic process.

Meeting Medical Needs

Our cutting-edge technology detects the superbug Pseudomonas aerunginosa in minutes. This speed and precision at the point of care fullfills an unmet need in respiratory medicine.

Nanodecal Solutions

Our technology provides accurate and timely information, enabling healthcare professionals to make informed decisions for the treatment of respiratory conditions more effectively.

Our Technology

Respiratory samples can be thick, making it difficult to analyze them quickly. Nanodecal addresses this challenge by using a unique method to liquefy these samples instantly. Traditional rapid tests may have limited sensitivity due to detecting only one bacterial antigen. Nanodecal's innovative nanosensors can identify whole cells, enhancing the test's accuracy. To get quantitative results from our tests, all you need is a smartphone and our free app for reading the results. This approach combines our expertise in rapid tests and computer vision to deliver an accurate and user-friendly experience.

Learn more about our technology

At Nanodecal, our rapid test is made possible by combining three breakthrough technologies pioneered in our lab.

Read more about our scientific work

The scientific foundation of our patented technology is build on our published work in high quality, peer-reviewed journals.

Unlocking the power of sputum liquefaction for respiratory disease testing

  • 1-2 minutes
  • Complete liquefaction
  • Mild conditions
  • No instruments
  • At the point of care

Adaptable for analyses with molecular methods, mass spectrometry, AMR testing and more. Validated for different lung biomarkers and pathogens
Available for licensing.

Detect Bacteria with dot blot

High sensitivity
Disperses biofilms

Detect Leukocytes with cytometry

Untouched cells
High cell viability

Detect Cytokines with ELISA

High sensitivity
Low background

Detect IgG and IGM with ELISA

High sensitivity
Not denaturing

Our Team

We are putting together a multidisciplinary team to bring Nanodecal's breakthrough biotech to market. Together, we will make a significant impact in the field of respiratory diagnostic tools.

Roberto de la Rica

CEO | CSO | Founder

I am committed to help Nanodecal grow so that our technology can help patients. I am thrilled by the idea of guiding therapeutic decisions using scientific evidence obtained on the spot.

Steven M. Russell

Regulatory Affairs Manager

I develop and maintain the quality management and risk management systems needed to inform decisions with real-world evidence. I am excited to be managing regulatory affairs to support the growth of Nanodecal.

Cristina Adrover

R&D | Founder

I'm a passionate R&D specialist and company founder, devoted to advancing healthcare through developing cutting-edge biosensor technology.

Andreu Vaquer

R&D | Founder

I am a founder of Nanodecal and dedicated to shaping the future through groundbreaking research, pioneering new frontiers in nanoparticle-based IVDs.

Antonio Clemente

R&D | Founder

Miguel Servet Researcher at Multidisciplinary Sepsis Group

Advisory Board

Marcio Borges

President of the Code Sepsis Foundation and Director of the Sepsis Area at FEPIMCTI

Fernando de Marcos

International Senior Executive and Fundraising Consultant

Borja García-Cosío

Coordinator of the National Strategy on COPD for the Balearic Islands

Antonio Oliver

Head of Clinical Microbiology at HUSE and world expert in Pseudomonas infections

Eva Martín

Regulatory Affairs Manager for Clinical Research and IP Strategy Consultant

Antonio Ornelas

Advisor for Life Sciences & Medical Technology for Venture Capital Co.

Supported By

Scientific Evidence

Our knowledge of existing medical needs and techonogical solutions is underpinned by our patents and peer-reviewed publications

Sensor Manufacturing Patent

Process for storing and releasing protein-decorated nanoparticles on paper substrates

Sample Treatment Patent

Method for liquifying a respiratory sample and for the subsequent detection of respiratory infections in said sample

RaPId Article 1

Nanoparticle Reservoirs for Paper-Only Immunosensors ACS Sensors 2020

RaPId Article 2

Nanoparticle transfer biosensors for the non-invasive detection of SARS-CoV-2 antigens trapped in surgical face masks.

RaPId Article 3

Paper biosensors for detecting elevated IL-6 levels in blood and respiratory samples from COVID-19 patients.

CataLiST Article 1

Rapid Detection of Pseudomonas aeruginosa Biofilms via Enzymatic Liquefaction of Respiratory Samples.

CataLiST Article 2

Optimized detection of lung IL-6 via enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients.

CataLiST Article 3

Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients.

MoCAS Article 1

Improving the Quantification of Colorimetric Signals in Paper-Based Immunosensors with an Open-Source Reader

MoCAS Article 2

Nanoparticle-Based Mobile Biosensors for the Rapid Detection of Sepsis Biomarkers in Whole Blood